Scientific deep-dive

Handgrip Strength and Sarcopenic Obesity

Over twelve months on semaglutide, handgrip strength rose 4.5 kg and sarcopenic obesity fell from 49% to 33%, while lean mass declined early then stabilized rather than continuing down.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
5 min read·1 citation

Almost everything written about muscle and these drugs measures mass on a scan. The SEMALEAN study measured something better: what people could do. Over twelve months on semaglutide 2.4 mg, handgrip strength improved by 4.5 kg, and the prevalence of sarcopenic obesity fell from 49% to 33%.[1]

What happened, in order

Fat mass fell 18% by month twelve. Lean mass declined by about 3 kg by month seven, then stabilized rather than continuing down.[1]

The lean-mass loss is front-loaded, and then it stops. It is not a slope that continues for as long as you take the drug.

That shape matters for the argument people are having. “These drugs eat your muscle” implies an ongoing process. What this describes is an early adjustment as body size falls, followed by a plateau. That is what you would expect if lean loss is a consequence of needing less muscle to move a smaller body.

The functional results

  • Handgrip strength rose 4.5 kg by month twelve. Grip strength is a standard, hard-to-fake proxy for whole-body strength and a well-validated predictor of outcomes.
  • Sarcopenic obesity fell from 49% to 33%. That is a net fall in a formal diagnosis: 22% of participants lost it by month twelve and 5% newly developed it.[1]
  • Resting energy expenditure normalized to lean mass rose between months seven and twelve, meaning the remaining tissue was not becoming metabolically sluggish.

This is consistent with a smaller study we covered in muscle volume versus muscle function, where psoas volume fell 9.3% while chair-rise time and walking speed both improved slightly. Two independent studies finding mass down and function up is a more useful pattern than either alone.

There is no control group. Everyone received the drug, so improvement cannot be attributed to it. People who lose 18% of their fat mass may grip harder because they are lighter and moving more, and repeated testing produces a learning effect. This is a strong signal in a design that cannot establish cause.

Who responded differently

Three subgroup findings stand out, and one is directly practical.

  1. Women lost more weight and fat mass, consistent with the randomized picture in who loses more weight.
  2. People with type 2 diabetes, or prior GLP-1 use, showed attenuated responses. The diabetes finding is well established. The prior-use one matters for anyone switching drugs (see switching).
  3. People with a history of bariatric surgery showed the most pronounced changes, which is relevant to the growing group taking these drugs after weight regain following surgery.

The prior-GLP-1 finding deserves particular attention because it is rarely mentioned. If you have taken one of these drugs before, the response to the next may be smaller than the trial figures suggest, because trial populations are typically drug-naive.

Frequently Asked Questions

This study found the opposite on a functional measure. Handgrip strength improved by 4.5 kg over twelve months and the prevalence of sarcopenic obesity fell from 49% to 33%, even though lean mass declined by about 3 kg early on.
Not here. Lean mass declined by around 3 kg by month seven and then stabilized rather than continuing down. That is an early adjustment followed by a plateau, which is what you would expect if the loss reflects needing less muscle to move a smaller body.
There was no control group, so improvement cannot be attributed to the drug. People who lose substantial fat may grip harder because they are lighter and more active, and repeated testing has a learning effect. It is a strong signal in a design that cannot establish cause.
Possibly not. People with prior GLP-1 use showed attenuated responses in this study, as did those with type 2 diabetes. Trial populations are usually drug-naive, so someone switching drugs may see less than the published figures suggest.
Having both excess fat and reduced muscle mass or function at the same time, a combination associated with worse outcomes than either alone. Nearly half the participants met the definition at baseline and a third after a year. That is a net change: 22% of participants lost the diagnosis and 5% newly developed it.

References

  1. 1.Alissou M, Demangeat T, Folope V, et al. Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study Diabetes, Obesity and Metabolism. 2026. PMID: 41068996.

Muscle Volume Versus Muscle Function on a GLP-1

Psoas muscle volume fell 9.3% over 24 weeks while chair-rise time and walking speed both edged better. Mass and function moved in opposite directions in the same people, and only one of them is what anybody wants.

6 min read

GLP-1 Drugs and HIV-Associated Lipohypertrophy: The Randomized Evidence

A phase 2b randomized trial found once-weekly semaglutide cut abdominal visceral fat by about 30.6% over 32 weeks in people with HIV-associated lipohypertrophy, alongside a 9.3% fall in psoas muscle volume that did not cost measurable function.

6 min read

GLP-1 Drugs After Spinal Cord Injury: Three People Treated, Two Not

In a controlled case series of five people with chronic spinal cord injury, three on weekly semaglutide lost weight, fat mass and visceral fat over 26 weeks while the two untreated participants gained on every measure.

5 min read

Muscle Loss: Drug Versus Dieting

Across 20 trials in 15,782 people, lean mass made up the same fraction of weight lost on incretin drugs as on dieting (p=0.42). Adding resistance training cut it from about a quarter to 17.5%.

6 min read

Bimagrumab Plus Semaglutide: The Muscle Question

The combination lost 17.8 kg at 48 weeks against 14.2 kg for semaglutide alone. But bimagrumab exists to change what you lose, and the published summary reports only how much.

6 min read

Collagen Peptides: What the Trials Show for Skin, Joints, Bone and Muscle

Pooled trials show better skin hydration with collagen peptides, but a 2025 meta-analysis found no effect in trials not funded by companies. Knee and other osteoarthritis pain eases modestly. For muscle, collagen did less than whey or pea protein, which matters on a GLP-1.

9 min read

Where to get semaglutide online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

9.1

Collective

From $59/mo + membership

Get started →
Read full review →
7.9

Luvo Health

Moving between compounded and brand without changing seller

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →